Larry Zeitlin

List of Publications by Year
in descending order

73	4,782	147801 31	102487 66
papers	citations	h-index	g-index

80	80	80	4769
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11.	3.3	6
2	Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana. MAbs, 2022, 14, 2013594.	5.2	7
3	Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Science Translational Medicine, 2022, 14, eabl5399.	12.4	16
4	Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight, 2022, 7, .	5.0	18
5	Special focus issue: passive immunization. Human Vaccines and Immunotherapeutics, 2022, 18, 2028517.	3.3	0
6	Rapid detection of an Ebola biomarker with optical microring resonators. Cell Reports Methods, 2022, 2, 100234.	2.9	9
7	Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. Pathogens, 2022, 11, 655.	2.8	5
8	Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial. PLoS Medicine, 2021, 18, e1003495.	8.4	34
9	Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
10	Combination therapy protects macaques against advanced Marburg virus disease. Nature Communications, 2021, 12, 1891.	12.8	37
11	Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nature Structural and Molecular Biology, 2021, 28, 426-434.	8.2	33
12	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell, 2021, 184, 3486-3501.e21.	28.9	39
13	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. Frontiers in Immunology, 2021, 12, 706757.	4.8	4
14	Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women. EBioMedicine, 2021, 69, 103478.	6.1	12
15	Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods in Enzymology, 2021, 660, 239-263.	1.0	5
16	Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV. Viruses, 2021, 13, 2231.	3.3	3
17	Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	7
18	Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. Nature Communications, 2020, 11, 3736.	12.8	11

#	Article	IF	Citations
19	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. Journal of Virology, 2020, 94, .	3.4	28
20	Engineering monoclonal antibody-based contraception and multipurpose prevention technologiesâ€. Biology of Reproduction, 2020, 103, 275-285.	2.7	23
21	Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies. PLoS Neglected Tropical Diseases, 2020, 14, e0007803.	3.0	19
22	Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin. Npj Vaccines, 2020, 5, 13.	6.0	12
23	Development of an antibody cocktail for treatment of Sudan virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3768-3778.	7.1	23
24	Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Scientific Reports, 2020, 10, 6201.	3.3	22
25	A Humanized Monoclonal Antibody Cocktail to Prevent Pulmonary Ricin Intoxication. Toxins, 2020, 12, 215.	3.4	13
26	Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. Cell Host and Microbe, 2020, 27, 976-991.e11.	11.0	43
27	Aerosol infection of Balb/c mice with eastern equine encephalitis virus; susceptibility and lethality. Virology Journal, 2019, 16, 2.	3.4	17
28	Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
29	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Cell Host and Microbe, 2019, 25, 39-48.e5.	11.0	83
30	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host and Microbe, 2019, 25, 49-58.e5.	11.0	82
31	Rescue of rhesus macaques from the lethality of aerosolized ricin toxin. JCI Insight, 2019, 4, .	5.0	22
32	ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus. Journal of Infectious Diseases, 2018, 218, 901-910.	4.0	26
33	Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. Journal of Infectious Diseases, 2018, 218, S565-S573.	4.0	13
34	Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition. Mucosal Immunology, 2018, 11, 1477-1486.	6.0	29
35	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	11.0	182
36	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	28.9	173

#	Article	IF	Citations
37	Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
38	Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. Aids, 2017, 31, 1505-1517.	2.2	22
39	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	28.9	145
40	Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Science Translational Medicine, 2017, 9, .	12.4	64
41	Susceptibility and Lethality of Western Equine Encephalitis Virus in Balb/c Mice When Infected by the Aerosol Route. Viruses, 2017, 9, 163.	3.3	9
42	Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Journal of Virology, 2016, 90, 7618-7627.	3.4	32
43	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Science Translational Medicine, 2016, 8, 329ra33.	12.4	78
44	Monoclonal antibody therapy for Junin virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4458-4463.	7.1	50
45	Humanized Monoclonal Antibody That Passively Protects Mice against Systemic and Intranasal Ricin Toxin Challenge. Vaccine Journal, 2016, 23, 795-799.	3.1	27
46	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology, 2016, 1, 16128.	13.3	92
47	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	6.4	80
48	3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology, 2016, 490, 49-58.	2.4	67
49	Antibody therapeutics for Ebola virus disease. Current Opinion in Virology, 2016, 17, 45-49.	5.4	45
50	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. Journal of Virology, 2016, 90, 266-278.	3.4	92
51	The emergence of antibody therapies for Ebola. Human Antibodies, 2015, 23, 49-56.	1.5	37
52	Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide. Journal of Immunological Methods, 2015, 422, 111-117.	1.4	9
53	Chimeric Plantibody Passively Protects Mice against Aerosolized Ricin Challenge. Vaccine Journal, 2014, 21, 777-782.	3.1	43
54	Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5992-5997.	7.1	107

#	Article	IF	Citations
55	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17182-17187.	7.1	173
56	Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 2014, 514, 47-53.	27.8	883
57	A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin. Toxicon, 2014, 92, 36-41.	1.6	16
58	Plant-Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease. Microbiology Spectrum, 2014, 2, AID-0004-2012.	3.0	14
59	Antibody-based concepts for multipurpose prevention technologies. Antiviral Research, 2013, 100, S48-S53.	4.1	12
60	Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail. Science Translational Medicine, 2013, 5, 199ra113.	12.4	199
61	Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs, 2013, 5, 263-269.	5.2	28
62	Multiantibody Strategies for HIV. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	7
63	Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18030-18035.	7.1	344
64	Emerging Antibody-based Products. Current Topics in Microbiology and Immunology, 2012, 375, 107-126.	1.1	15
65	Synthetic Human Monoclonal Antibodies toward Staphylococcal Enterotoxin B (SEB) Protective against Toxic Shock Syndrome. Journal of Biological Chemistry, 2012, 287, 25203-25215.	3.4	61
66	Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20690-20694.	7.1	210
67	Emerging antibody products and Nicotiana manufacturing. Hum Vaccin, 2011, 7, 349-356.	2.4	71
68	Production of pharmaceuticalâ€grade recombinant aprotinin and a monoclonal antibody product using plantâ€based transient expression systems. Plant Biotechnology Journal, 2010, 8, 638-654.	8.3	169
69	Second-generation HIV microbicides: Continued development of griffithsin. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6029-6030.	7.1	33
70	Preventing infectious disease with passive immunization. Microbes and Infection, 2000, 2, 701-708.	1.9	86
71	Using Monoclonal Antibodies to Prevent Mucosal Transmission of Epidemic Infectious Diseases. Emerging Infectious Diseases, 1999, 5, 54-64.	4.3	88
72	A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nature Biotechnology, 1998, 16, 1361-1364.	17.5	264

#	Article	IF	Citations
73	Plant-Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease. , 0, , 411-425.		0